References
- Ahmad NS, Ramli A, Islahudin F, Paraidathathu T (2013). Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia. Patient Prefer Adherence, 7, 525-30.
- AlGhurair SA, Hughes CA, Simpson SH, Guirguis LM (2012). A systematic review of patient self reported barriers of adherence to antihypertensive medications using the World Health Organization Multidimensional Adherence Model. J Clin Hypertens, 14, 877-86. https://doi.org/10.1111/j.1751-7176.2012.00699.x
- Atkins L, Fallowfield L (2006). Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer, 42, 2271-6. https://doi.org/10.1016/j.ejca.2006.03.004
- Bhattacharya D, Easthall C, Willoughby KA, Small M, Watson S (2012). Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract, 18, 333-42. https://doi.org/10.1177/1078155211436022
- Cramer JA (1998). Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging, 12, 7-15. https://doi.org/10.2165/00002512-199812010-00002
- Cramer JA, Roy A, Burrell A, et al (2008). Medication compliance and persistence: terminology and definitions. Value in Health, 11, 44-7. https://doi.org/10.1111/j.1524-4733.2007.00213.x
- DiMatteo MR (2004). Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol, 23, 207-18. https://doi.org/10.1037/0278-6133.23.2.207
- Dusing R (2001). Adverse events, compliance, and changes in therapy. Curr Hypertens Rep, 3, 488-92. https://doi.org/10.1007/s11906-001-0011-0
- Hassan NB, Hasanah CI, Foong K, et al (2006). Identification of psychosocial factors of noncompliance in hypertensive patients. J Hum Hypertens, 20, 23-9. https://doi.org/10.1038/sj.jhh.1001930
- Krolop L, Ko YD, Schwindt PF, et al (2013). Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study. BMJ Open, 3.
- Lim GCC, Yahaya H, Lim TO (2002). The First Report of the National Cancer Registry: Cancer Incidence in Malaysia 2002 Ministry of Health, Malaysia, Kuala Lumpur.
- Omar ZA, Tamin NSI (2007). National Cancer Registry Report: Malaysia Cancer Statistics - Data and Figure 2007, Ministry of Health Malaysia, Putrajaya.
- Omar ZA, Ali ZM, Tamin NSI (2006). Malaysia Cancer Statistics- Data and Figure (Peninsular Malaysia) 2006, Ministry of Health, Malaysia, Putrajaya.
- Partridge AH, Archer L, Kornblith AB, et al (2010). Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol, 28, 2418-22. https://doi.org/10.1200/JCO.2009.26.4671
- Payne SA (1992). A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med, 35, 1505-9. https://doi.org/10.1016/0277-9536(92)90053-S
- Ramli A, Ahmad NS, Paraidathathu T (2012). Medication adherence among hypertensive patients of primary health clinics in Malaysia. Patient Prefer Adherence, 6, 613-22.
- Roche (2014). Xeloda: Indications. [Online] Available from:http://www.xeloda.com/hcp/# [Accessed February 3rd].
- Roder DM, de Silva P, Zorbas HN, et al (2012). Adherence to recommended treatments for early invasive breast cancer: decisions of women attending surgeons in the breast cancer audit of Australia and New Zealand. Asian Pac J Cancer Prev, 13, 1675-82. https://doi.org/10.7314/APJCP.2012.13.4.1675
- Ruddy K. Mayer E, Partridge A (2009). Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin, 59, 56-66. https://doi.org/10.3322/caac.20004
- Sabate E (2003). World Health Organization: Adherence to Long Term Therapies: Evidence for Action, World Health Oraganization, Geneva.
- Spoelstra SL, Given CW (2011). Assessment and measurement of adherence to oral antineoplastic agents. Semin Oncol Nurs, 27, 116-32. https://doi.org/10.1016/j.soncn.2011.02.004
- Staddon AP (2011). Challenges of ensuring adherence to oral therapy in patients with solid malignancies. Comm Oncol, 8, 246.
- Stiggelbout A M, De Haes J (2001). Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol, 19, 220-30.
- Thivat E, Van Praagh I, Belliere A, et al (2013). Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors. Oncol, 84, 67-74. https://doi.org/10.1159/000342087
- Twelves C, Wong A, Nowacki MP, et al (2005). Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med, 352, 2696-704. https://doi.org/10.1056/NEJMoa043116
- Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A (2013). Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev, 39, 610-21. https://doi.org/10.1016/j.ctrv.2012.12.014
- Walko CM, Lindley C (2005). Capecitabine: a review. Clin Ther, 27, 23-44. https://doi.org/10.1016/j.clinthera.2005.01.005
- WHO (2013). WHO: Cancer. [Online] Available from: http://www.who.int/cancer/en/ [Accessed 28 September].
- Winterhalder R, Hoesli P, Delmore G, et al (2011). Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncol, 80, 29-33. https://doi.org/10.1159/000328317
Cited by
- Prevention of Nausea and Vomiting: Methods and Utility after Surgery in Cancer Patients? vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2629
- Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice vol.5, pp.1, 2016, https://doi.org/10.1186/s40064-016-1851-z